Cannabis and Neurodegenerative Diseases

Janet Medical Research

 

Neurodegenerative Diseases and Medical Marijuana

What Are Neurodegenerative Diseases?

Neurodegenerative diseases are those which result mainly from dysfunction of the central nervous system (the CNS, made up of the brain and spinal cord) as a result of damage to neurons, the primary cells of this system that communicate with each other to send signals throughout the brain and body. Damage to neurons of the CNS can result in a decreased ability to send signals to the peripheral, autonomic, and enteric nervous systems, which make it possible for us to move, touch, digest, breathe, react to and sense our environment, and in general, to live.

When cells of the central nervous system are destroyed and/or not able to communicate with each other efficiently and effectively, symptoms such as cognition and memory impairment, muscle incoordination, weakness, spasticity [i.e. tight muscles and exaggerated reflexes], paralysis [i.e. an inability to move], rigidity [i.e. tight muscles], and more can occur. These symptoms can cause substantial decreases in quality of life for patients, and even death when involving reduction in function of important physiological processes like breathing and heart function. Neurodegenerative disorders are so debilitating partially because neurons are one of the few cell types with a very limited ability to regenerate (along with heart cells and skeletal muscle cells). In most cases, once neurons have been destroyed, they cannot grow back.

“If left unchecked 30 years from now, more than 12 million Americans will suffer from neurodegenerative diseases.” – Harvard Neurodiscovery Center

Examples of neurodegenerative diseases include Alzheimer’sParkinson’s, Huntington’samyotrophic lateral sclerosis (ALS, also known as “Lou Gehrig’s Disease’), spinal muscular atrophy, prion disease, and others. While multiple sclerosis (MS) has been thought to stem primarily from an autoimmune response (one in which the body starts attacking itself), there is mounting evidence that it is a disease caused by a mixture of an autoimmune and primary neurodegeneration process.

A significant amount of research on cannabis has been conducted on the plant’s potential harms in relation to brain function. However, the evidence suggests that not only are long-term, clinically significant cognitive deficits unlikely if use begins in adulthood, especially in the absence of chronic and excessive use, but cannabinoid medicine may actually prove effective in halting or reversing debilitating neurodegenerative disorders. Note: Cognitive declines as a result of use have generally been conducted using recreational users who self-report frequency of use and smoke marijuana of unknown potency and quality; studying marijuana use with alternative delivery methods (e.g. vaporization, ingestion) and controlled frequency of use with whole-plant cannabis of known ratio/concentration/potency in an adult patient population may yield vastly different results than those  discovered to date which have indicated harm.full_spectrum_tincture

According to an article published by the Harvard Neurodiscovery Center, “If left unchecked 30 years from now, more than 12 million Americans will suffer from neurodegenerative diseases.” It is therefore imperative that the medical and scientific communities continue to extensively research any and all potentially successful therapies for these disease processes.

Cannabinoid Therapy for Neurodegenerative Diseases

Extensive research on the impact of endocannabinoid system modulation and its effects on neurodegenerative disorders has occurred in the past several years. In 2014, British Journal of Pharmacology published a review titled “The influence of cannabinoids on generic traits of neurodegeneration”, in which the authors concluded the following:

ths-ecs-for-ths2-1024x753“Signalling from the CB1 and CB2 [i.e. cannabinoid] receptors are known to be involved in the regulation of Ca2+ [calcium] homeostasis [i.e. the mechanism by which systems are kept balanced], mitochondrial function [i.e. function of components of cells that produce energy], trophic [i.e. growth] support and inflammatory status… while other receptors gated [i.e. modulated/controlled] by cannabinoids… are gaining interest in their anti-inflammatory properties. Through multiple lines of evidence, this evolutionarily conserved neurosignalling system has shown neuroprotective capabilities and is therefore a potential target for neurodegenerative disorders.” While the current article briefly touches on the evidence that exists for the potential of cannabinoid therapy as treatment for neurodegenerative disorders, the BJP article will provide a more extensive overview.

“[E]levation of cannabinoid receptor activity either by pharmacological blockade of the degradation of cannabinoids or by receptor agonists could be a promising strategy for slowing down the progression of brain ageing and for alleviating the symptoms of neurodegenerative disorders.” — Dr. Andras Bilkei-Gorzo

Cannabinoid-receptors-280x300Another review published in 2012 in Philosophical Transactions of the Royal Society (source of the graphic below) discusses that cannabis may exert neuroprotective effects through mitochondrial regulation, anti-inflammatory and antioxidant (i.e. agents that prevent free radical damage) properties, and clearance of damaged cells and molecules in the brain. The author also noted that signaling of the endocannabinoid system (ECS) may decrease as people age, and therefore decreased function of the ECS may be a partial cause for age-related cognitive decline. According to the author, Dr. Andras Bilkei-Gorzo, “[E]levation of cannabinoid receptor activity either by pharmacological blockade of the degradation of cannabinoids [i.e. keeping cannabinoids active and in the brain for a longer amount of time] or by receptor agonists [i.e. receptor activation] could be a promising strategy for slowing down the progression of brain ageing and for alleviating the symptoms of neurodegenerative disorders.”

Additionally, a study published in July 2014 in the Journal of Neuroscience Research found more evidence to support the potential of cannabinoids to act as anti-inflammatory and neuroprotective agents, showing that ultralow (non-psychoactive) doses of THC were protective against “neuroinflammation-induced cognitive damage” (this study and was reviewed previously on Medical Jane).

In the image below, ROS stands for “reactive oxygen species”, which are created as intermediate products in natural physiological processes, but can cause damage to cells and tissues. “Synapses” are the junction between two neurons where signals are passed/communicated, and “organelles” are components of cells that have specific functions (e.g. mitochondria are organelles).

neurodeg

Conclusion

Given the highly favorable safety profile of whole-plant cannabis, and the severely debilitating symptoms caused by certain neurodegenerative diseases which could potentially be alleviated by its use, whole-plant cannabis medicine may be a safe and useful additional therapy for patients with certain neurodegenerative diseases who are finding it difficult to control their symptoms with standard therapy. Increased research on cannabinoid medicine and modulation of the endocannabinoid system in relation to neurodegeneration has the potential to lead to novel therapies which may help to prevent progression, and potentially initiation, of these diseases.

For information on how you can advocate, expectations, and safety in considering whole-plant medical cannabis use, click here

Please click the following links to access Medical Jane articles reviewing the evidence for the potential of cannabinoid medicine in treatment of the following neurodegenerative diseases: ALS, Alzheimer’sParkinson’s, and Huntington’sFor an overview of the potential of cannabinoid medicine in managing multiple sclerosis, please see Medical Jane’s previous coverage of this topic here.

Article by: 

Posted at:   http://www.medicaljane.com/2014/11/11/cannabis-classroom-neurodegenerative-disease-and-medical-marijuana/

STUDY

The influence of cannabinoids on generic traits of neurodegeneration

  1. S G Fagan* and
  2. V A Campbell

Keywords:

  • cannabinoids;
  • neurodegeneration;
  • neuroinflammation;
  • excitotoxicity;
  • mitochondrial dysfunction;
  • neurogenesis;
  • Alzheimer’s disease;
  • Parkinson’s disease;
  • Huntington’s disease

Abstract

In an increasingly ageing population, the incidence of neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease are rising. While the aetiologies of these disorders are different, a number of common mechanisms that underlie their neurodegenerative components have been elucidated; namely neuroinflammation, excitotoxicity, mitochondrial dysfunction and reduced trophic support. Current therapies focus on treatment of the symptoms and attempt to delay the progression of these diseases but there is currently no cure. Modulation of the endogenous cannabinoid system is emerging as a potentially viable option in the treatment of neurodegeneration. Endocannabinoid signalling has been found to be altered in many neurodegenerative disorders. To this end, pharmacological manipulation of the endogenous cannabinoid system, as well as application of phytocannabinoids and synthetic cannabinoids have been investigated. Signalling from the CB1 and CB2 receptors are known to be involved in the regulation of Ca2+ homeostasis, mitochondrial function, trophic support and inflammatory status, respectively, while other receptors gated by cannabinoids such as PPARγ, are gaining interest in their anti-inflammatory properties. Through multiple lines of evidence, this evolutionarily conserved neurosignalling system has shown neuroprotective capabilities and is therefore a potential target for neurodegenerative disorders. This review details the mechanisms of neurodegeneration and highlights the beneficial effects of cannabinoid treatment.

Study can be read at:  http://onlinelibrary.wiley.com/doi/10.1111/bph.12492/full

Summary

commoncanabinoids2Neurodegenerative diseases are a heterogeneous group of age-related disorders. While AD, PD and HD have a variety of different genetic and environmental causes, the principal factor involved is the progressive and severe loss of neurons. It is widely accepted that neuroinflammation, excitotoxicity and oxidative stress are key mediators of neurodegeneration, and impaired neurogenesis as well as reduced trophic support leave neuronal systems unable to cope. The eCB system is emerging as a key regulator of many neuronal systems that are relevant to neurodegenerative disorders. Activation of CB1 receptors regulates many neuronal functions such as Ca2+ homeostasis and metabolic activity while the CB2 receptor is mainly involved in regulating the inflammatory response.

Here, we have put forward the mechanisms of neurodegeneration in the three most prevalent neurodegenerative disorders, AD, PD and HD, as well as showing the vulnerability of the brain as a result of age. We have summarized evidence of the beneficial role of modulating the cannabinoid system to reduce the burden of neurodegeneration. Pharmacological modulation of the eCB system ( Figure 3) has been shown to reduce chronic activation of the neuroinflammatory response, aid in Ca2+ homeostasis, reduce oxidative stress, mitochondrial dysfunction and the resulting proapoptotic cascade, while promoting neurotrophic support.

figure

Figure 3. Chemical structures of the common CB receptor agonists.